Evidence map›Paper›PMID 41923650›Full record

ArticleCancer reports (Hoboken, N.J.)2026

Ovarian Cancer Mortality Predictors in Public Oncology Centers, Addis Ababa, Ethiopia: A Case-Control Study.

Abrham Tesfaye Habteyes, Jembere Tesfaye Deressa, Roza Teshome Kassa

Abstract read
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Abrham Tesfaye HabteyesDepartment of Nursing, College of Health Sciences, Ethiopian Defence University, Bishoftu, Ethiopia.ORCID 0009-0007-2911-748X
Jembere Tesfaye DeressaSchool of Nursing and Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.ORCID 0000-0001-5059-1759
Roza Teshome KassaSchool of Nursing and Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.ORCID 0000-0002-5864-7785

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer remains the most lethal gynecologic cancer and has the worst prognosis among all female reproductive malignancies worldwide. In Ethiopia, ovarian cancer is the third most prevalent malignancy among women, following breast and cervical cancers. Despite extensive research on the topic, evidence regarding the determinants of mortality among ovarian cancer patients remains limited. Therefore, the primary aim of this study was to identify predictors of ovarian cancer mortality among patients receiving care at oncology centers in Addis Ababa, Ethiopia.

methodsA facility-based case-control study was conducted among women with ovarian cancer enrolled at oncology centers in Addis Ababa. A total of 137 cases and 274 controls were selected using the stratified sampling method. Data were extracted from patient records with a structured data extraction tool. The effect of each predictor variable on ovarian cancer mortality was estimated using binary logistic regression at the 5% level of significance and the final model's goodness of fit was tested with the likelihood ratio test.

resultsThis study included 411 ovarian cancer patients. Advanced FIGO stage (III&IV) (AOR: 2.85, 95% CI: [1.27-6.39]), advanced age (≥ 60) (AOR: 8.71; 95% CI: [3.89-19.48]), and comorbidity (AOR: 3.24, 95% CI: [1.69-6.19]) were found to be independent predictors of mortality, whereas urban residency (AOR: 0.36; 95% CI: [0.19-0.66]) and nonepithelial histological type (AOR: 0.12, 95% CI: [0.03-0.53]) were found to be protective factors. Moreover, patients not receiving pain medication had lower odds of mortality (AOR: 0.39; 95% CI: [0.22-0.69]).

conclusionsMultivariable logistic regression analysis identified the following factors as significant predictors of mortality among ovarian cancer patients: advanced FIGO stage, comorbidities, advanced age, nonepithelial histology, pain medication, and urban residency. Therefore, early detection through timely clinical evaluation and diagnosis and treatment should be emphasized. Moreover, patients identified with significant predictors of mortality should receive targeted clinical attention and closer follow-up to improve survival outcomes.

Indexed as

Ovarian NeoplasmsAdultAgedCase-Control StudiesEthiopiaFemaleHumansMiddle AgedNeoplasm StagingPrognosisRisk Factorsdeterminantsmortalityoncology centersovarian cancer

Identifiers

PMID41923650
PMCPMC13045442

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.